Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer

Debu Tripathy, MD
Published: Monday, Jun 19, 2017



Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

With many mature data being presented in the near future, Tripathy says that trials with combinations of standard chemotherapy and immunotherapy, trastuzumab (Herceptin) and pertuzumab (Perjeta), are promising.

On the other hand, Tripathy adds, estrogen receptor-positive/HER2-negative breast cancers have been shown to be less immunogenic.
 


Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

With many mature data being presented in the near future, Tripathy says that trials with combinations of standard chemotherapy and immunotherapy, trastuzumab (Herceptin) and pertuzumab (Perjeta), are promising.

On the other hand, Tripathy adds, estrogen receptor-positive/HER2-negative breast cancers have been shown to be less immunogenic.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x